Insights from Veeva Projected Prescription and Procedure Data:
Commercial Momentum and Market Adoption

Powered by projected prescription and procedure data in Compass Prescriber and National, this report shows estimated unique patient starts and healthcare providers (HCPs) for products treating Myasthenia Gravis, as well as those products' other on-label conditions.

Compass includes non-retail channels, offering a more complete picture of commercial momentum for the gMG market, where there is a mix of in-office infusions and self-administrations. The performance metrics below represent cumulative, 2026 year-to-date totals through September.

Brand Manufacturer Disease Area YTD
Patient Starts		 YTD
HCP Counts
Imaavy Janssen Myasthenia Gravis 1,107 415
Acquired Hemolytic Anemias 4 4
Rystiggo UCB Myasthenia Gravis 748 403
Soliris AstraZeneca Myasthenia Gravis 433 356
Atypical Hemolytic Uremic Syndrome 268 402
Neuromyelitis Optica Spectrum Disorder 100 104
Paroxysmal Nocturnal Hemoglobinuria 69 135
Ultomiris AstraZeneca Myasthenia Gravis 2,087 1,132
Atypical Hemolytic Uremic Syndrome 809 843
Paroxysmal Nocturnal Hemoglobinuria 482 693
Neuromyelitis Optica Spectrum Disorder 468 347
Uplizna Amgen Myasthenia Gravis 853 259
Neuromyelitis Optica Spectrum Disorder 812 386
Immunoglobulin G4-related Disease 733 322
Vyvgart Argenx Myasthenia Gravis 3,138 1,655
Vyvgart Hytrulo Argenx Myasthenia Gravis 2,242 1,227
Polyneuropathies / Peripheral Neuropathy 2,335 1,069
Zilbrysq UCB Myasthenia Gravis 480 141
Data through September 30, 2026

Additional recent launches also available:

  • Arynta (Azurity)
  • Avlayah (Denali Therapeutics)
  • Awiqli (Novo Nordisk)
  • Bixlenvo (Gilead Sciences)
  • Favlyxa (Avyxa Pharma)
  • Hepcludex (Gilead Sciences)
  • Lipfendra (Merck)
  • mFLUSIVA (Moderna)
  • Rasonque (Revolution Medicines)
  • Xocova (Shionogi)
  • Zenbexus (Bristol Myers Squibb)

To learn more about these launch brands or explore custom market analysis, contact anthony.billinger@veeva.com.

Veeva Compass Prescriber & Compass National are syndicated data products that leverage two patented projection methodologies to estimate prescription, procedure, and patient volume within the United States. Centers for Medicare & Medicaid Services (CMS) drug utilization data is accessed through Virtual Research Data Center (VRDC), and leveraged as part of these methodologies. These estimates are fully refreshed on a weekly and monthly basis.
Let's Partner

Interested in learning more about
how Veeva can help?

Contact Us